Antipsoriatic peptide - Biozeus
Latest Information Update: 28 Oct 2023
At a glance
- Originator Unknown
- Developer Biozeus
- Class Antipsoriatics; Peptides
- Mechanism of Action Nitric oxide stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for clinical-Phase-Unknown development in Psoriasis in Brazil (Topical)
- 09 Sep 2020 Antipsoriasis peptide - Biozeus is available for licensing as of 09 Sep 2020. http://biozeus.com.br/en/about-mission-strategy/